LU83128A1 - Compositions pharmaceutiques contenant un derive de naphtyridine - Google Patents
Compositions pharmaceutiques contenant un derive de naphtyridine Download PDFInfo
- Publication number
- LU83128A1 LU83128A1 LU83128A LU83128A LU83128A1 LU 83128 A1 LU83128 A1 LU 83128A1 LU 83128 A LU83128 A LU 83128A LU 83128 A LU83128 A LU 83128A LU 83128 A1 LU83128 A1 LU 83128A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- compound
- pharmaceutical compositions
- derivative
- naphtyridine
- compositions containing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000026680 Metabolic Brain disease Diseases 0.000 claims description 2
- 230000003542 behavioural effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000005054 naphthyridines Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- XYGBKMMCQDZQOZ-UHFFFAOYSA-M sodium;4-hydroxybutanoate Chemical compound [Na+].OCCCC([O-])=O XYGBKMMCQDZQOZ-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000000496 anti-anoxic effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8003011 | 1980-02-12 | ||
| FR8003011A FR2475394A1 (fr) | 1980-02-12 | 1980-02-12 | Compositions pharmaceutiques contenant l'hexahydro-1, 2, 3, 3a, 4, 5, 6h indolo (3, 2, 1 - d. e) (1, 5) naphtyridinone - 6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU83128A1 true LU83128A1 (fr) | 1982-09-10 |
Family
ID=9238471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU83128A LU83128A1 (fr) | 1980-02-12 | 1981-02-11 | Compositions pharmaceutiques contenant un derive de naphtyridine |
Country Status (11)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU84664A1 (fr) * | 1983-02-25 | 1984-11-08 | Onmichem S A | Alkyl-4-indolonaphtyridines et leur application therapeutique |
| CA1329597C (en) * | 1986-12-22 | 1994-05-17 | Dagmar Hoeltje | Derivatives of tetrahydropyrido[1,2-a]indole |
| US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2358146A1 (fr) * | 1976-04-13 | 1978-02-10 | Synthelabo | Derives de la tetrahydro-1,2,3,3a indolo(3,2,1-de) (1,5)naphtyridine |
-
1980
- 1980-02-12 FR FR8003011A patent/FR2475394A1/fr active Granted
-
1981
- 1981-02-10 AU AU67145/81A patent/AU6714581A/en not_active Abandoned
- 1981-02-11 DE DE19813104884 patent/DE3104884A1/de active Pending
- 1981-02-11 LU LU83128A patent/LU83128A1/fr unknown
- 1981-02-11 BE BE0/203762A patent/BE887468A/fr unknown
- 1981-02-11 IL IL62114A patent/IL62114A0/xx unknown
- 1981-02-11 GB GB8104135A patent/GB2068731A/en not_active Withdrawn
- 1981-02-11 ZA ZA00810919A patent/ZA81919B/xx unknown
- 1981-02-11 IT IT19667/81A patent/IT1135422B/it active
- 1981-02-11 NL NL8100645A patent/NL8100645A/nl not_active Application Discontinuation
- 1981-02-12 JP JP2000581A patent/JPS56127313A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA81919B (en) | 1982-03-31 |
| DE3104884A1 (de) | 1982-01-14 |
| FR2475394B1 (enrdf_load_stackoverflow) | 1982-05-21 |
| FR2475394A1 (fr) | 1981-08-14 |
| NL8100645A (nl) | 1981-09-01 |
| IL62114A0 (en) | 1981-03-31 |
| IT1135422B (it) | 1986-08-20 |
| GB2068731A (en) | 1981-08-19 |
| JPS56127313A (en) | 1981-10-06 |
| IT8119667A0 (it) | 1981-02-11 |
| AU6714581A (en) | 1981-08-20 |
| BE887468A (fr) | 1981-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0851855B9 (fr) | Derives acyles de la melatonine et d'analogues en tant que medicament | |
| EP0031741A1 (fr) | Nouveaux iminoacides substitués, leurs procédés de préparation et leur emploi comme inhibiteurs d'enzymes | |
| CH637927A5 (fr) | Derives de 4-amino-5-alkylsulfonyl ortho-anisamides et leurs procedes de preparation. | |
| WO2002081453A1 (fr) | Hiohydantoïnes et leur utilisation dans le traitement du diabete | |
| EP0172096A1 (fr) | Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique | |
| EP0110781B1 (fr) | (Amino-2 éthyl)-6 benzoxazolinones substituées, leur préparation et une composition pharmaceutique les contenant | |
| EP0779284A1 (fr) | Nouveaux dérivés de 2-naphthamides et leurs applications thérapeutiques comme agonistes des récepteurs D3 | |
| EP0008249B1 (fr) | Dérivés de fluorènes et fluoranthènes, leur procédé de préparation et leur application en thérapeutique | |
| EP0021857B1 (fr) | Dérivés de l'indole, leur préparation et medicaments les contenant | |
| EP0018857B1 (fr) | Pyrimido et imidazo-pyrido-indole-diones, leur préparation et leur application en thérapeutique | |
| FR2898358A1 (fr) | Association d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2 par modulation allosterique et leurs utilisations comme produits medicaux | |
| LU83128A1 (fr) | Compositions pharmaceutiques contenant un derive de naphtyridine | |
| EP0671173A1 (fr) | Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs | |
| FR2610932A1 (fr) | Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament | |
| CH622795A5 (enrdf_load_stackoverflow) | ||
| CH675998A5 (enrdf_load_stackoverflow) | ||
| CH615673A5 (enrdf_load_stackoverflow) | ||
| LU83775A1 (fr) | Derives de naphtyridine,leur preparation et leur application en therapeutique | |
| CH632763A5 (en) | Triazolothiadiazine derivatives and processes for preparing them | |
| FR2640139A1 (fr) | Application de benzamides substitues comme gastromoteurs | |
| FR2526793A1 (fr) | Nouveaux a-(n-pyrrolyl)-acides et leurs sels et esters, utiles comme medicaments et procede de la preparation de tels composes | |
| WO2002092598A1 (fr) | DERIVES DE DIHYDROIMIDAZO [5,1-A]-β-CARBOLINE, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION A TITRE DE MEDICAMENT | |
| US4024259A (en) | 3-Anilino-2,4-diazabicyclo[3.2.1]octenes | |
| EP0001940A1 (fr) | Dérivés de l'éburnaménine, leur préparation et leur application en thérapeutique | |
| CH648295A5 (fr) | Acides 2-amino-3-(alkylthiobenzyl)-phenylacetiques et leurs derives. |